396 related articles for article (PubMed ID: 11712877)
1. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
Sanders GD; Hlatky MA; Every NR; McDonald KM; Heidenreich PA; Parsons LS; Owens DK
Ann Intern Med; 2001 Nov; 135(10):870-83. PubMed ID: 11712877
[TBL] [Abstract][Full Text] [Related]
2. Summaries for patients. Cost-effectiveness of implantable defibrillators versus the drug amiodarone to prevent abnormal heart rhythms after heart attack.
Ann Intern Med; 2001 Nov; 135(10):S-56. PubMed ID: 11757494
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death.
Owens DK; Sanders GD; Harris RA; McDonald KM; Heidenreich PA; Dembitzer AD; Hlatky MA
Ann Intern Med; 1997 Jan; 126(1):1-12. PubMed ID: 8992917
[TBL] [Abstract][Full Text] [Related]
4. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
[TBL] [Abstract][Full Text] [Related]
5. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.
Owens DK; Sanders GD; Heidenreich PA; McDonald KM; Hlatky MA
Am Heart J; 2002 Sep; 144(3):440-8. PubMed ID: 12228780
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of implantable cardioverter-defibrillators.
Sanders GD; Hlatky MA; Owens DK
N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis.
Smith T; Jordaens L; Theuns DA; van Dessel PF; Wilde AA; Hunink MG
Eur Heart J; 2013 Jan; 34(3):211-9. PubMed ID: 22584647
[TBL] [Abstract][Full Text] [Related]
8. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.
Colquitt JL; Mendes D; Clegg AJ; Harris P; Cooper K; Picot J; Bryant J
Health Technol Assess; 2014 Aug; 18(56):1-560. PubMed ID: 25169727
[TBL] [Abstract][Full Text] [Related]
9. Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone.
Caro JJ; Ward A; Deniz HB; O'Brien JA; Ehreth JL
Value Health; 2007; 10(1):13-22. PubMed ID: 17261112
[TBL] [Abstract][Full Text] [Related]
10. Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists?
Stevenson WG; Ridker PM
JAMA; 1996 Aug; 276(6):481-5. PubMed ID: 8691557
[TBL] [Abstract][Full Text] [Related]
11. Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada.
Deniz HB; Ward A; Jaime Caro J; Alvarez P; Sadri H
Curr Med Res Opin; 2009 Mar; 25(3):617-26. PubMed ID: 19232036
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
[TBL] [Abstract][Full Text] [Related]
13. Are implantable cardioverter- defibrillators cost-effective?
Naik AM; Peter CT
Curr Cardiol Rep; 2000 Jul; 2(4):341-5. PubMed ID: 10953269
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction.
Pedretti RF; Migliori GB; Mapelli V; Daniele G; Podrid PJ; Tramarin R
J Am Coll Cardiol; 1998 Jun; 31(7):1481-9. PubMed ID: 9626823
[TBL] [Abstract][Full Text] [Related]
15. Are implantable cardioverter-defribrillators always superior to amiodarone?
Doggrell SA
Expert Opin Pharmacother; 2003 Nov; 4(11):2111-4. PubMed ID: 14596664
[TBL] [Abstract][Full Text] [Related]
16. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.
Cowie MR; Marshall D; Drummond M; Ferko N; Maschio M; Ekman M; de Roy L; Heidbuchel H; Verboven Y; Braunschweig F; Linde C; Boriani G
Europace; 2009 Jun; 11(6):716-26. PubMed ID: 19359333
[TBL] [Abstract][Full Text] [Related]
17. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
Klein H; Auricchio A; Reek S; Geller C
Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
[TBL] [Abstract][Full Text] [Related]
18. Clinical criteria for predicting benefit of ICD/PM in post myocardial infarction patients: an AVID and CAST analysis.
Hallstrom AP; Wyse DG; McAnulty J; ;
J Interv Card Electrophysiol; 2008 Dec; 23(3):159-66. PubMed ID: 18810620
[TBL] [Abstract][Full Text] [Related]
19. Amiodarone: clinical trials.
Naccarelli GV; Wolbrette DL; Patel HM; Luck JC
Curr Opin Cardiol; 2000 Jan; 15(1):64-72. PubMed ID: 10666663
[TBL] [Abstract][Full Text] [Related]
20. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.
Gali WL; Sarabanda AV; Baggio JM; Ferreira LG; Gomes GG; Marin-Neto JA; Junqueira LF
Europace; 2014 May; 16(5):674-80. PubMed ID: 24481778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
